Last10K.com

Ampio Pharmaceuticals, Inc. (AMPE) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

Ampio Pharmaceuticals, Inc.

CIK: 1411906 Ticker: AMPE
Document And Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Feb. 14, 2020
Jun. 28, 2019
Document And Entity Information [Abstract]   
Document Type10-K  
Document Period End DateDec. 31, 2019  
Entity Registrant NameAMPIO PHARMACEUTICALS, INC.  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Filer CategoryAccelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companyfalse  
Entity Well-known Seasoned IssuerNo  
Entity Interactive Data CurrentYes  
Entity Public Float  $ 54.2
Entity Common Stock, Shares Outstanding 158,780,993 
Entity Central Index Key0001411906  
Current Fiscal Year End Date--12-31  
Document Fiscal Year Focus2019  
Document Fiscal Period FocusFY  
Amendment Flagfalse  

View differences made from one year to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ampio Pharmaceuticals, Inc..

Continue

Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Other
Filter Subcategory:
All
Expense
Other
Inside Ampio Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Operations
Statements Of Stockholders' Equity
Statements Of Stockholders' Equity (Parenthetical)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Detail)
Accounts Payable And Accrued Expenses (Tables)
Basis Of Presentation
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Cro Contract (Detail)
Commitments And Contingencies - Employment Agreements (Detail)
Commitments And Contingencies - Rent Expense (Detail)
Commitments And Contingencies - Summary Of Commitments And Contingencies (Detail)
Commitments And Contingencies - Summary Of Reconciliation Of Company's Undiscounted Payments For Facility Lease And Carrying Amount Of Lease Liability (Detail)
Common Stock
Common Stock (Capital Stock Narrative) (Detail)
Common Stock (Common Stock Issued For Services) (Detail)
Common Stock (Controlled Equity Offering) (Detail)
Common Stock (Public Offering Narrative) (Detail)
Common Stock (Shelf Registration Narrative) (Detail)
Common Stock (Summarizes The Company's Remaining Authorized Shares Available - (Detail)
Common Stock (Summary Of Company???S Sales Under The Equity Distribution Agreement) (Detail)
Common Stock (Tables)
Earnings Per Share
Earnings Per Share (Detail)
Earnings Per Share (Tables)
Earnings Per Share - Narrative (Detail)
Employee Benefit Plan
Equity Instruments
Equity Instruments (Tables)
Equity Instruments - Activity Of Plan (Detail)
Equity Instruments - Assumptions Used In Computing Fair Value Of All Options Granted (Detail)
Equity Instruments - Options, Additional Information (Detail)
Equity Instruments - Stock Option Activity (Detail)
Equity Instruments - Summary Of Stock Options Outstanding And Exercisable (Detail)
Equity Instruments - Summary Of Stock-Based Compensation Expense (Detail)
Fair Value Considerations
Fair Value Considerations (Tables)
Fair Value Considerations - Financial Assets And Liabilities (Detail)
Fair Value Considerations - Sets Forth A Reconciliation Of Changes (Detail)
Fixed Assets
Fixed Assets (Detail)
Fixed Assets (Tables)
Fixed Assets - Depreciation Expenses (Detail)
Going Concern
Going Concern (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Deferred Tax Assets And Liabilities (Detail)
Income Taxes - Reconciliation Of Effective Tax Rate (Detail)
Litigation
Prepaid Expenses And Other
Prepaid Expenses And Other (Detail)
Prepaid Expenses And Other (Tables)
Subsequent Events
Subsequent Events - (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Detail)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Impairment Of Long-Lived Assets (Detail)
Warrants
Warrants (Tables)
Warrants - (Detail)
Warrants - Assumptions For Warrants Issued (Detail)
Warrants - Warrants Activity (Detail)
Ticker: AMPE
CIK: 1411906
Form Type: 10-K Annual Report
Accession Number: 0001558370-20-001123
Submitted to the SEC: Fri Feb 21 2020 6:14:27 AM EST
Accepted by the SEC: Fri Feb 21 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ampe/0001558370-20-001123.htm